NEW YORK, August 12, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Actavis PLC (NYSE: ACT), UnitedHealth Group Inc. (NYS: UNH), Bristol-Myers Squibb Co. (NYSE: BMY), Celgene Corporation (NASDAQ: CELG) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5652-100free.
Actavis PLC Research Reports
On August 6, 2014, shares of Actavis PLC (Actavis) fell 3.80% to end the session at $206.51, a day after the pharma Company predicted lower-than-expected sales and earnings for 2015. For 2015, the Company expects net revenue to be approximately $15 billion and non-GAAP EPS to be between $15.60 and $16.80. However, analysts polled by Thomson Reuters expect the Company to report 2015 EPS of $16.61 on revenue of $15.59 billion. Further on August 5, 2014, Actavis reported Q2 2014 financial results with net revenue of $2.7 billion versus $2.0 million in Q2 2013. Net income available to ordinary shareholders stood at $48.7 million or $0.28 per diluted share, compared to a loss of $564.8 million or $4.27 per diluted share, in Q2 2013. On a non-GAAP basis, EPS for Q2 2014 was $3.42 versus $2.01 in Q2 2013. The full research reports on Actavis are available to download free of charge at:
UnitedHealth Group Inc. Research Reports
On August 7, 2014, UnitedHealth Group Inc. (UnitedHealth) stated that the Company is collaborating with Centura Health and Colorado Health Neighborhoods - Centura Health's provider network of more than 2,500 employed and independent affiliated physicians - to provide health care services, which improves quality and reduces costs for nearly 17,000 UnitedHealthcare plan participants in the state. According to the Company, UnitedHealthcare, Centura Health and Colorado Health Neighborhoods will manage evidence-based care, ensuring that the primary care physicians, specialists and facilities are aligned with the Institute for Healthcare Improvement's (IHI's) "Triple Aim" objective: increase patient satisfaction, improve the health of the population and reduce the cost of health care. UnitedHealth informed that this new accountable care organization will help shift Colorado's health care system from one based on volume of care to one that rewards quality and value. The full research reports on UnitedHealth are available to download free of charge at:
Bristol-Myers Squibb Co. Research Reports
On August 4, 2014, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) and Allied Minds joined hands to form a new venture to identify and promote research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S. The Company stated that the jointly owned enterprise, Allied-Bristol Life Sciences LLC, will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development, and ultimately approved therapies that address serious diseases. "Allied-Bristol Life Sciences LLC brings together cutting-edge ideas, BioPharma experience and drug discovery expertise focused on maximizing the potential of new scientific approaches to addressing serious disease," said Carl Decicco, Senior Vice President and Head of Discovery, Bristol-Myers Squibb. "We believe this new venture will enhance the translation of early-stage academic research and will ultimately help advance important potential new medicines more efficiently." The full research reports on Bristol-Myers Squibb are available to download free of charge at:
Celgene Corporation Research Reports
On August 7, 2014, shares of Celgene Corporation (Celgene) fell 1.06% from its previous day's close to end the trading session at $85.22. A total of 3.8 million shares were traded, higher than previous day's trading volume of the 2.7 million shares. During the session, the shares touched an intraday low of $84.85 and a high of $86.48. The Company is trading near its 52-week high of $90.50. Over the past 12-months, the stock has returned 15.67%, largely in line with the gains in NASDAQ Composite, which gained 17.49%, during the same time period. The full research reports on Celgene are available to download free of charge at:
Aetna Inc. Research Reports
On August 1, 2014, Aetna Inc. (Aetna) issued a press release stating that the Company and NYUPN Clinically Integrated Network, LLC have agreed to form an accountable care collaboration aimed at improving patient care and reduce health care costs. As per the release, effective July 1, 2014, NYUPN and its more than 1,800 clinical faculty and health care professionals affiliated with NYU Langone Medical Center and University Physicians Network (UPN) began working with Aetna to ensure enhanced care coordination and care quality. The Company informed that it will financially reward NYUPN for quality health outcomes for approximately 24,000 members in both commercial and Medicare Advantage plans. David Kobus, Aetna Senior Vice President, New York Network said, "This new collaboration with NYUPN will provide their physicians with useful information that will support more patient outreach, better care coordination and a health care experience that is simpler and more effective." The full research reports on Aetna are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review